Selected article for: "ARDS respiratory distress syndrome and associated disease"
Author: Avdeev, Sergey N.; Trushenko, Natalia V.; Chikina, Svetlana Yu; Tsareva, Natalia A.; Merzhoeva, Zamira M.; Yaroshetskiy, Andrey I.; Sopova, Violetta I.; Sopova, Margarita I.; Rosenberg, Oleg A.; Schermuly, Ralph Theo; Kosanovic, Djuro
Title: Beneficial effects of inhaled surfactant in patients with COVID-19-associated acute respiratory distress syndrome
  • Cord-id: 2fkq5fbe
  • Document date: 2021_5_29
    • ID: 2fkq5fbe
    Snippet: BACKGROUND: We have investigated the use of nebulized surfactant as a potential therapeutic option for the patients with coronavirus disease 2019 (COVID-19)-associated acute respiratory distress syndrome (ARDS) undergoing non-invasive ventilation. METHODS: The patients were divided into 2 groups: surfactant (n = 33) and control (n = 32). The subjects in the surfactant group received the inhaled surfactant at daily dose of 150–300 mg. The oxygenation parameters and several clinical outcomes wer
    Document: BACKGROUND: We have investigated the use of nebulized surfactant as a potential therapeutic option for the patients with coronavirus disease 2019 (COVID-19)-associated acute respiratory distress syndrome (ARDS) undergoing non-invasive ventilation. METHODS: The patients were divided into 2 groups: surfactant (n = 33) and control (n = 32). The subjects in the surfactant group received the inhaled surfactant at daily dose of 150–300 mg. The oxygenation parameters and several clinical outcomes were analyzed. RESULTS: On the 5 day of therapy, PaO(2)/FiO(2) improved significantly in the surfactant group compared to the control group (184 (155–212) mmHg vs 150 (91–173) mmHg, p = 0.02). The inhaled surfactant significantly reduced the need for transfer of patients to intensive care units (24.2% vs 46.9%, p = 0.05) and invasive mechanical ventilation (18.2% vs 40.6%, p = 0.04). Even more, the nebulized surfactant shortened the length of non-invasive ventilation (7 (3–13) days vs 11 (5–22) days, p = 0.02) and time spent in hospital (18 (16–27) days vs 26 (21–31) days, p = 0.003) in patients suffering from COVID-19-linked ARDS. CONCLUSIONS: Our preliminary data provided indications that inhaled surfactant therapy may represent a promising option for patients with COVID-19-associated ARDS. However, larger clinical trials are crucially needed.

    Search related documents:
    Co phrase search for related documents
    • absolute value and acute respiratory distress syndrome: 1, 2
    • absolute value and acute sars respiratory syndrome coronavirus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • acute ards respiratory distress syndrome and adaptive innate: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22
    • acute ards respiratory distress syndrome and admission record: 1, 2
    • acute ards respiratory distress syndrome and admission score: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20
    • acute ards respiratory distress syndrome and lung collapse: 1, 2, 3
    • acute ards respiratory distress syndrome develop and adaptive innate: 1, 2
    • acute ards respiratory distress syndrome develop and admission score: 1
    • acute respiratory distress syndrome and adaptive innate: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory distress syndrome and admission record: 1, 2
    • acute respiratory distress syndrome and admission score: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory distress syndrome and local immunity: 1
    • acute respiratory distress syndrome and lung collapse: 1, 2, 3, 4, 5, 6, 7
    • acute sars respiratory syndrome coronavirus and adaptive innate: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute sars respiratory syndrome coronavirus and admission record: 1
    • acute sars respiratory syndrome coronavirus and admission score: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24
    • acute sars respiratory syndrome coronavirus and local immunity: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • acute sars respiratory syndrome coronavirus and lung collapse: 1
    • adaptive innate and local immunity: 1, 2, 3, 4, 5